CN109563052A - 5-氨基-2,3-二氢噻嗪-1,4-二酮的结晶体 - Google Patents

5-氨基-2,3-二氢噻嗪-1,4-二酮的结晶体 Download PDF

Info

Publication number
CN109563052A
CN109563052A CN201780023199.1A CN201780023199A CN109563052A CN 109563052 A CN109563052 A CN 109563052A CN 201780023199 A CN201780023199 A CN 201780023199A CN 109563052 A CN109563052 A CN 109563052A
Authority
CN
China
Prior art keywords
acid
pharmaceutical composition
luminol
agent
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780023199.1A
Other languages
English (en)
Chinese (zh)
Inventor
T·马丁
J·布罗伊
J·弗莱斯纳
W·布里施
J·冯韦格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metriopharm AG
Original Assignee
Metriopharm AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metriopharm AG filed Critical Metriopharm AG
Priority to CN202211145086.8A priority Critical patent/CN115536594A/zh
Publication of CN109563052A publication Critical patent/CN109563052A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1044—Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Materials Engineering (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Optics & Photonics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780023199.1A 2016-02-16 2017-02-15 5-氨基-2,3-二氢噻嗪-1,4-二酮的结晶体 Pending CN109563052A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211145086.8A CN115536594A (zh) 2016-02-16 2017-02-15 5-氨基-2,3-二氢噻嗪-1,4-二酮的结晶体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16000379.4 2016-02-16
EP16000379 2016-02-16
PCT/EP2017/000227 WO2017140430A1 (en) 2016-02-16 2017-02-15 Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211145086.8A Division CN115536594A (zh) 2016-02-16 2017-02-15 5-氨基-2,3-二氢噻嗪-1,4-二酮的结晶体

Publications (1)

Publication Number Publication Date
CN109563052A true CN109563052A (zh) 2019-04-02

Family

ID=55398165

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780023199.1A Pending CN109563052A (zh) 2016-02-16 2017-02-15 5-氨基-2,3-二氢噻嗪-1,4-二酮的结晶体
CN202211145086.8A Pending CN115536594A (zh) 2016-02-16 2017-02-15 5-氨基-2,3-二氢噻嗪-1,4-二酮的结晶体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211145086.8A Pending CN115536594A (zh) 2016-02-16 2017-02-15 5-氨基-2,3-二氢噻嗪-1,4-二酮的结晶体

Country Status (8)

Country Link
US (1) US11111218B2 (enExample)
EP (1) EP3416951B1 (enExample)
JP (2) JP7034079B2 (enExample)
KR (1) KR102535960B1 (enExample)
CN (2) CN109563052A (enExample)
CA (1) CA3011767C (enExample)
ES (1) ES2797299T3 (enExample)
WO (1) WO2017140430A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111587243A (zh) * 2018-01-11 2020-08-25 麦翠奥制药公司 用于增溶5-氨基-2,3-二氢-1,4-酞嗪二酮的方法
CN115052602A (zh) * 2020-01-31 2022-09-13 麦翠奥制药公司 5-胺基-2,3-二氢-1,4-酞嗪二酮在治疗罕见的慢性发炎性肺病中的用途
CN115190793A (zh) * 2020-01-31 2022-10-14 麦翠奥制药公司 5-胺基-2,3-二氢-1,4-酞嗪二酮用于吸入性治疗发炎性肺疾病的应用
CN116075306A (zh) * 2020-06-10 2023-05-05 麦翠奥制药公司 用于治疗冠状病毒感染的化合物
TWI899145B (zh) 2020-01-31 2025-10-01 瑞士商麥翠奧製藥公司 5-胺基-2,3-二氫-1,4-酞嗪二酮或其藥學上可接受的鹽用於吸入性治療肺疾病之應用、氣霧劑及其製造方法以及套件

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201804132D0 (en) * 2018-03-15 2018-05-02 Secr Defence Forensic analysis of an object for chemical and biological agents
KR20220158030A (ko) 2020-03-25 2022-11-29 메트리오팜 아게 급성 폐손상 치료용 5-아미노-2,3-디히드로-1,4-프탈라진디온
EP3981405A1 (en) 2020-10-08 2022-04-13 MetrioPharm AG Compound for the treatment of coronaviral infections
CN116963738A (zh) 2020-12-02 2023-10-27 麦翠奥制药公司 用于SARS-CoV-2感染的后遗症的预防和治疗的鲁米诺
US20230087473A1 (en) * 2021-09-22 2023-03-23 Hemant N. Joshi Composition of suspoemulsion formulation of anthelmintic drugs with essential oils for naso-pulmonary administration
EP4193994A1 (en) 2021-12-08 2023-06-14 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections
US20250064801A1 (en) * 2022-01-07 2025-02-27 Metropharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of congenital muscular dystrophies
EP4209219A1 (en) 2022-01-07 2023-07-12 MetrioPharm AG Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione
EP4248963A1 (en) 2022-03-25 2023-09-27 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a fumaric acid ester
EP4483879A1 (en) 2023-06-29 2025-01-01 MetrioPharm AG 5-amino-2,3-dihydro-1,4-phthalazinedione for the prophylaxis and treatment of thrombotic disorders
WO2025067689A1 (en) 2023-09-26 2025-04-03 Metriopharm Ag 5-amino-2,3-dihydro-1,4-phthalazinedione for the treatment of infections with an rna virus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646918A (zh) * 2002-04-25 2005-07-27 Roc进口公司 探测和定位血迹的方法以及为探测血迹设计的组合物
CN102971300A (zh) * 2010-03-01 2013-03-13 梅特里奥药品股份公司 5-氨基-2,3-二氢-(2,3-二氮杂萘)-1,4-二酮钠盐的晶型、含有它们的药物制剂以及所述晶型的生产方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH683966A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanze attive in agenti anti-ipossici e di difesa.
WO2011123776A2 (en) * 2010-04-01 2011-10-06 Guthery B Eugene Method for detecting occult blood
JP2017537958A (ja) * 2014-12-18 2017-12-21 メトリオファーム アーゲー ５−アミノ−２，３−ジヒドロフタラジン１，４−ジオンナトリウム塩の結晶形態、同一物を含む医薬製剤、及びこの形態の製造ための方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646918A (zh) * 2002-04-25 2005-07-27 Roc进口公司 探测和定位血迹的方法以及为探测血迹设计的组合物
CN102971300A (zh) * 2010-03-01 2013-03-13 梅特里奥药品股份公司 5-氨基-2,3-二氢-(2,3-二氮杂萘)-1,4-二酮钠盐的晶型、含有它们的药物制剂以及所述晶型的生产方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HENRICH H. PARADIES: "《The Crystal and Molecular Structure of 3-Aminophthalhydrazide (Luminol)》", 《BERICHTE DER BUNSEN-GESELLSCHAFT-PHYSICAL CHEMISTRY CHEMICAL PHYSICS》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111587243A (zh) * 2018-01-11 2020-08-25 麦翠奥制药公司 用于增溶5-氨基-2,3-二氢-1,4-酞嗪二酮的方法
CN115052602A (zh) * 2020-01-31 2022-09-13 麦翠奥制药公司 5-胺基-2,3-二氢-1,4-酞嗪二酮在治疗罕见的慢性发炎性肺病中的用途
CN115190793A (zh) * 2020-01-31 2022-10-14 麦翠奥制药公司 5-胺基-2,3-二氢-1,4-酞嗪二酮用于吸入性治疗发炎性肺疾病的应用
TWI899145B (zh) 2020-01-31 2025-10-01 瑞士商麥翠奧製藥公司 5-胺基-2,3-二氫-1,4-酞嗪二酮或其藥學上可接受的鹽用於吸入性治療肺疾病之應用、氣霧劑及其製造方法以及套件
CN116075306A (zh) * 2020-06-10 2023-05-05 麦翠奥制药公司 用于治疗冠状病毒感染的化合物

Also Published As

Publication number Publication date
JP7331067B2 (ja) 2023-08-22
JP7034079B2 (ja) 2022-03-11
KR20180107277A (ko) 2018-10-01
JP2022037005A (ja) 2022-03-08
KR102535960B1 (ko) 2023-05-23
EP3416951B1 (en) 2020-04-08
CA3011767C (en) 2024-02-06
CN115536594A (zh) 2022-12-30
EP3416951A1 (en) 2018-12-26
US11111218B2 (en) 2021-09-07
WO2017140430A1 (en) 2017-08-24
JP2019509268A (ja) 2019-04-04
CA3011767A1 (en) 2017-08-24
US20200369624A1 (en) 2020-11-26
ES2797299T3 (es) 2020-12-01

Similar Documents

Publication Publication Date Title
CN109563052A (zh) 5-氨基-2,3-二氢噻嗪-1,4-二酮的结晶体
CN109071461A (zh) 制备5-氨基-2,3-二氢噻嗪-1,4-二酮结晶体的方法
EP2822539B1 (en) Nanocrystalline solid dispersion compositions
EP2120890B1 (de) Beschichtete pellets
EP3248602A1 (en) Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
CN103561720A (zh) 己烯雌酚剂型及其在前列腺癌或乳腺癌的治疗中的用途
CN107847437B (zh) 用于治疗疼痛的塞来昔布口服组合物
Ali et al. Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote
CA3238847A1 (en) New pharmaceutical device for use in intranasal administration
CN101712707B (zh) 罗红霉素三种晶型物质、制法以及药物组合物与用途
JP2024516340A (ja) Ｓａｒｓ－ｃｏｖ－２感染の後遺症の予防と治療のためのルミノール
CN104473881A (zh) 克拉霉素掩味微丸制剂及其制备方法
CN103565746A (zh) 一种安普霉素脂质体及其制备方法
Tran et al. pH-Sensitive polymeric systems for controlling drug release in nocturnal asthma treatment
HK40001510B (en) Method for producing a crystalline form of 5-amino-2, 3-dihydrophthalazine-1, 4-dione
HK40001510A (en) Method for producing a crystalline form of 5-amino-2, 3-dihydrophthalazine-1, 4-dione
HK40001511A (en) Crystalline form of 5-amino-2,3-dihydrophtalazine-1,4-dione
CN118510521A (zh) 布地奈德和5-氨基-2,3-二氢-1,4-酞嗪二酮的组合
CN103130853A (zh) 罗红霉素晶c型物质、制法以及药物组合物与用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40001511

Country of ref document: HK